Region specific galanin receptor/neuropeptide Y Y1 receptor interactions in the tel- and diencephalon of the rat. Relevance for food consumption.
The aim of this work was to determine the interactions between NPY and GAL receptor (GALR) subtypes in the hypothalamus and the amygdala using quantitative receptor autoradiography to analyze the binding characteristics of NPY-Y1 and Y2 receptor subtypes in the presence and absence of GAL. Food intake in satiated animals was evaluated after intraventricular co-injections of GAL and NPY-Y1 or Y2 agonists. The expression of c-Fos IR in both regions was also investigated. GAL decreases NPY-Y1 agonist binding in the arcuate nucleus by about 15% (p<0.01), but increases NPY-Y1 agonist binding in amygdala (18%) (p<0.01). These effects were blocked with the GAL antagonist M35. Y2-agonist binding was not modified by GAL. GAL blocked the food intake induced by the Y1 agonist (p<0.01). Co-injections of Y1 agonist and GAL also reduced the c-Fos expression induced by the Y1 agonist in the arcuate nucleus and the dorsomedial hypothalamic nucleus but increased c-Fos expression in amygdala. These results indicate the existence of antagonistic interactions between GALR and NPY-Y1 receptors in the hypothalamus and their functional relevance for food intake. In contrast, a facilitatory interaction between GALR and Y1 receptors exists in the amygdala which may be of relevance for fear related behaviour.
Parrado
C
C
Department of Histology, University of Málaga, Faculty of Medicine, Campus de Teatinos s/n, Malaga 29080, Spain.
Díaz-Cabiale
Z
Z
García-Coronel
M
M
Agnati
L F
LF
Coveñas
R
R
Fuxe
K
K
Narváez
J A
JA
D000679:Amygdala / Q000187:drug effects / Q000378:metabolism*; D000704:Analysis of Variance; D000818:Animals; D001345:Autoradiography / Q000379:methods; D001920:Bradykinin / Q000031:analogs & derivatives / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004435:Eating / Q000187:drug effects / Q000502:physiology*; D019004:Galanin / Q000494:pharmacology; D007031:Hypothalamus / Q000187:drug effects / Q000378:metabolism*; D007091:Image Processing, Computer-Assisted; D008297:Male; D009478:Neuropeptide Y / Q000494:pharmacology; D010446:Peptide Fragments / Q000494:pharmacology; D011485:Protein Binding / Q000187:drug effects; D016760:Proto-Oncogene Proteins c-fos / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D044088:Receptors, Galanin / Q000037:antagonists & inhibitors / Q000378:metabolism*; D017476:Receptors, Neuropeptide Y / Q000819:agonists / Q000378:metabolism*
D009478:Neuropeptide Y; D010446:Peptide Fragments; D016760:Proto-Oncogene Proteins c-fos; D044088:Receptors, Galanin; D017476:Receptors, Neuropeptide Y; C062924:neuropeptide Y (13-36); C097212:neuropeptide Y-Y1 receptor; C074069:galanin-(1-13)-bradykinin-(2-9)-amide; D019004:Galanin; D001920:Bradykinin